arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Kymera Therapeutics, Inc.

KYMR
$115.41 ▼ -6.60 (-5.41%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
30 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Neutral
auto_awesome

Analytical Summary

Kymera Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $11.3B
Dividend Yield —
Revenue Growth 466.4% ↗
Op. Margin -116.3% ↗
ROIC -4.0% ↗
FCF / Share $-0.56 ↗
Trailing P/E —
Price / Book 6.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$65.00M
↑ +466.4% —
Net Income Profit after all expenses
$-61.21M
↑ +20.1% —
Operating Margin Operating profit as % of sales
-116.3%
↑ +52.5% —
FCF / Share Free cash flow per share
$-0.56
↑ +26.2% —

Health Breakdown

Returns ↑
28
Financial Health ↓
4
Cash Quality ↓
51

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 8 years · 30 quarters